Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.
about
Evaluation of extended interval dosing aminoglycosides in the morbidly obese populationPharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature ReviewObesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.Dosing of antibacterial agents in obese adults: does one size fit all?The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.Pharmacokinetics of Antimicrobials in Obese Children.Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.A gentamicin order form improves its usePopulation pharmacokinetics of tobramycinAminoglycoside dosing weight correction factors for patients of various body sizes.Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsCefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjectsDevelopment of a dosing strategy for enoxaparin in obese patients.What is the best size descriptor to use for pharmacokinetic studies in the obese?Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.Acyclovir-induced acute renal failure and the importance of an expanding waist linePharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Antimicrobial dosing considerations in obese adult patients.Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.The effects of obesity on drug pharmacokinetics in humans.Implications of obesity for drug therapy: limitations and challenges.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Antibiotic dosing in obesity: the search for optimum dosing strategies.Interaction of obesity and infections.Aminoglycoside dosing considerations in intensive care unit patients.Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inEvaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.Failure of a nomogram to achieve target aminoglycoside concentrations.Management of aminoglycosides in the intensive care unit.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Pharmacokinetic estimation for therapeutic dosage regimens (PETDR)--a software program designed to determine intravenous drug dosage regimens for veterinary applications.Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.Drug dosing in obese adults.Study of relationship between volume of distribution and body weight application to amikacin.
P2860
Q29006722-9FBED80E-DFAB-40EE-80BE-B1069423852CQ29248398-B49E6641-B900-4D6E-9631-BFDC07CF69FBQ30277073-41A0C5EC-14E5-44E6-9A42-5CC68A5A15D9Q30362353-B17B4E27-94B0-4671-93B9-E9B30AB27507Q33763123-55BD5DA2-7529-4EDA-B227-5A076AFDB619Q33855312-997E357E-6CD8-44E2-966B-1A9A9E243BA6Q33995500-C4E1522A-F1AE-4F8E-A5B1-5F0064084784Q34188676-2DFC07F0-603E-4A6F-8E02-8862E6D6C09EQ34397757-3B5C0973-502A-410D-9117-C3146A02157EQ35111974-9A93FE70-A9FE-46DE-BE6E-F5F97E68D005Q35120597-C7835B94-B538-425C-90EF-25084CB6A372Q35191383-B802CA9D-D831-47BD-A865-DE94D9F541EBQ35340953-4B6F080F-EE1F-47DD-8B45-D4616311312CQ35746176-A630DEDA-2C14-4D4F-8EE1-D269D04251E7Q35825624-EBEF1D10-504B-4601-A1A1-71C7DE399768Q35826324-1017CC84-4E1B-4B83-BAF2-28E88DC09FAEQ35826839-FBC28996-4551-4804-A815-118E64556489Q35867436-AA4BE57A-6B76-4252-8FAC-46E4FBEAEE5EQ35974514-42B2572A-01BE-4261-9C28-ACA07C2F4C75Q36053463-9DE9849E-FFFE-46E8-8C0A-D61AE8099859Q36247129-3D5119C6-94EB-40C2-A8C6-A681BBF7644EQ36892796-EA6C683E-7594-4DFD-8A10-545465D10B01Q37120010-E88C598E-1595-4551-8093-F9CB4E2DBE3FQ37771799-617BE03C-8015-463E-9AA3-68F715120728Q37854751-00FF3587-EFA9-4D3B-90AD-95C02389C0EEQ37883897-FADCB9FE-8556-4528-B33D-BC5E06BCB07DQ38019839-AAF43ED6-017D-45BF-8782-4B05BD2F0C9BQ38247400-244AF6F8-4C48-45F1-ACA8-D5970C802C1DQ38397264-58D84923-7DAD-4171-A7EF-8D43CA4081C4Q38583848-B7B0BF97-7F1B-47BA-81F7-5622FEA4CB60Q40794034-CA87D7B0-0AE0-400C-9CF0-EA61B9201015Q41349399-518350B3-6926-4DE4-930C-9F9A4212CB72Q41559648-FD1C2582-6493-4671-8D31-54ABA317DD86Q42908644-9CA0FE4C-30B3-42D6-903E-C1CD51F677B0Q42908869-136699A6-376B-414C-AF7D-252B00B87C5AQ44455948-279B3750-DB6B-49F3-B01B-D83C2F6E4D84Q44861249-281A70B2-B9BA-4664-BE17-979B3E0534B7Q45978260-601C89D7-5D2E-4D5B-9623-2980E566A81EQ47154923-813E07B6-9D01-4120-9241-538E32A44A08Q47180268-26E929F9-76E4-48A0-992C-3A8F944EE4C7
P2860
Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Influence of weight on aminogl ...... t and morbidly obese patients.
@en
type
label
Influence of weight on aminogl ...... t and morbidly obese patients.
@en
prefLabel
Influence of weight on aminogl ...... t and morbidly obese patients.
@en
P2093
P356
P1476
Influence of weight on aminogl ...... t and morbidly obese patients.
@en
P2093
D A Simonowitz
E P Dellinger
W A Edwards
P2888
P304
P356
10.1007/BF00542215
P577
1983-01-01T00:00:00Z